NOVAVAX INC Income (Loss) from Continuing Operations before Income Taxes, Domestic
NOVAVAX INC (NVAX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $426.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- NOVAVAX INC income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $426.28M.
- NOVAVAX INC income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$261.91M.
- NOVAVAX INC income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$628.98M.
- NOVAVAX INC income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$712.18M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $426.28M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$261.91M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$628.98M 10-K · filed 2026-02-26 |
| 2022-12-31 | -$712.18M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$1.63B 10-K · filed 2024-02-28 |
| 2020-12-31 | -$455.25M 10-K · filed 2023-02-28 |
| 2019-12-31 | -$124.19M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |